Heron Therapeutics (HRTX) EBT Margin (2016 - 2025)
Historic EBT Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 10.71%.
- Heron Therapeutics' EBT Margin rose 28800.0% to 10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 198500.0%. This contributed to the annual value of 9.71% for FY2024, which is 777600.0% up from last year.
- Per Heron Therapeutics' latest filing, its EBT Margin stood at 10.71% for Q3 2025, which was up 28800.0% from 4.4% recorded in Q2 2025.
- Over the past 5 years, Heron Therapeutics' EBT Margin peaked at 10.23% during Q4 2024, and registered a low of 269.43% during Q2 2021.
- In the last 5 years, Heron Therapeutics' EBT Margin had a median value of 79.31% in 2023 and averaged 109.52%.
- In the last 5 years, Heron Therapeutics' EBT Margin tumbled by -527200bps in 2021 and then soared by 1914100bps in 2022.
- Heron Therapeutics' EBT Margin (Quarter) stood at 259.2% in 2021, then soared by 74bps to 67.79% in 2022, then skyrocketed by 56bps to 29.85% in 2023, then soared by 134bps to 10.23% in 2024, then plummeted by -205bps to 10.71% in 2025.
- Its last three reported values are 10.71% in Q3 2025, 4.4% for Q2 2025, and 8.11% during Q1 2025.